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| INTRODUC TI ON
Von Willebrand disease (VWD) is the most common inherited bleeding disorder diagnosed in humans. 1 This autosomally inherited disorder is characterized by quantitative or qualitative defects of Von Willebrand factor (VWF) and concomitant lower FVIII levels. Von Willebrand factor is essential for both primary and secondary hemostasis as it contributes to platelet adhesion and aggregation at sites of injury, resulting in platelet plug formation. Moreover, it acts as a chaperone protein for FVIII, protecting it from proteolysis in the circulation. 2, 3 The current VWD classification is based on observed VWF abnormalities. Whereas type 1 VWD describes a partial and type 3 VWD a complete quantitative VWF deficiency, type 2 VWD comprises several qualitative VWF defects. Von Willebrand disease is mainly characterized by mucocutaneous bleeding and bleeding after trauma or surgery. Available treatment focuses on normalization of VWF and FVIII levels in cases of acute bleeding, when trauma occurs, or in surgery. The VWF and FVIII levels can be increased by administration of desmopressin, which stimulates endogenous release, or by replacement therapy with intravenously administered exogenous VWF concentrate with or without FVIII. 4 Prophylactic treatment is rarely necessary and usually restricted to type 3 VWD patients.
A widely used plasma-derived VWF concentrate in patients with VWD is Haemate P ® or Humate P ® . 5 This concentrate contains both VWF and FVIII in a ratio of 2.4:1. Interindividual variability in achieved levels after infusion of this VWF/FVIII-containing concentrate has been reported by several investigators, both in the on-demand treatment of bleeding and in the surgical setting. [6] [7] [8] [9] This variability can be explained by both the interindividual differences in PK of the exogenous VWF/FVIII-containing concentrate and the interindividual differences in residual endogenous VWF and FVIII levels. Moreover, endogenous FVIII levels, which are known to vary unpredictably because of FVIII release from the endothelium after induced stress, trauma, or surgery, can differ significantly within an individual patient and between individuals. This variability hampers adequate dosing of VWF/FVIII concentrate, leading to achieved levels that may be higher or lower than targeted. 6 Subsequently this may lead to an increased risk of thrombosis or bleeding, respectively.
In addition, patient and societal burden of treatment are unnecessarily high as a result of frequent monitoring of plasma FVIII and VWF levels and more consumption of concentrate than necessary. 6 The current challenges to achieve the required target levels in VWD patients using this specific VWF/FVIII concentrate call for additional tools to dose more adequately. Population PK modeling and subsequent maximum a posteriori Bayesian analysis could be promising tools to reach individualize care in VWD patients who need to undergo surgery.
Historically, perioperative dosing of VWD patients with VWF/ FVIII concentrates has been based on FVIII levels for a variety of reasons. First, generally FVIII plasma levels were presumed more important in preventing perioperative bleeding. 10 Second, product labels only contained information on FVIII potency. Finally, more practically, the more rapid availability of FVIII level results in most laboratories made FVIII-based dosing a more feasible guide for replacement therapy with VWF/FVIII concentrate. However, nowadays some researchers recommend that especially during the first 36 postoperative hours, VWF activity also needs to be measured because the presence of sufficient VWF activity can be important for the aggregation of platelets during primary hemostasis and therefore initial wound closure. 3, 11 Sufficient FVIII levels are subsequently required for complete wound healing and are therefore often monitored during the whole perioperative period. [12] [13] [14] Dutch national guidelines have adopted these general principles and describe FVIII and VWF targets for the first 36 h after the surgery and FVIII targets for the further monitored postoperative period. 13 The aim of the study is to assess the population PK of FVIII activity levels after perioperative administration of a specific VWF/FVIII concentrate and to identify any patient, surgical, or treatment factors Society of Anesthesiologists (ASA) classification (ASA class >2), and increased duration of surgery were associated with decreased FVIII clearance.
Conclusion: This population PK model derived from real world data adequately describes FVIII levels following perioperative administration of the FVIII/VWF plasmaderived concentrate (Haemate ® P/Humate P ® ) and will help to facilitate future dosing in VWD patients.
K E Y W O R D S
Haemate P, individualized medicine, pharmacokinetics, surgery, von Willebrand disease Essentials • In many Von Willebrand disease (VWD) patients, perioperative factor VIII (FVIII) and von Willebrand factor levels are outside set targets.
• A population pharmacokinetic model for Haemate P based on FVIII levels was developed.
• The FVIII levels after Haemate P administration were adequately described by the population pharmacokinetic model.
• The population pharmacokinetic model could facilitate more accurate perioperative dosing for VWD patients.
correlating with the PK parameters of FVIII. The population model can be a starting point for the individualization of replacement therapy during the perioperative period in VWD patients and may be especially useful when only FVIII targets apply.
| ME THODS

| Data
The data used to construct this population PK model were obtained from a multicenter retrospective cohort study performed by the OPTI-CLOT study group, conducted in five Academic Haemophilia Treatment Centers in the Netherlands. 6 This first data set is referred to as the index data set and was used for the development of this FVIII-based population PK model. Additionally, an extra data set from the Erasmus University Medical Center Rotterdam (n = 20) was collected; it was used for external validation of the developed FVIII-based population PK model. This data set will be referred to as the validation data set. The combination of both data sets was used to build the final FVIII-based population PK model. All data were collected between 2000 and 2018 and acquired in accordance with the Dutch rules and regulations for Good Clinical Practice.
All VWD patients included in this study underwent a surgical intervention requiring replacement therapy with VWF/FVIII concentrate (Haemate P ® ). The data consisted of FVIII plasma levels, patient demographics, surgical characteristics, and treatment information. Patient demographics included sex, age, height, weight, blood group, hemoglobin levels, baseline VWF:antigen (VWF:Ag), VWF activity (VWF:Act), and FVIII activity levels (lowest levels ever measured in the patient), renal function and hepatic function (characterized by aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, albumin, urea, and creatinine), type of VWD as diagnosed following the national guidelines, and surgical risk classification based on the ASA physical status classification system. 13 Surgical characteristics consisted of type, severity and duration of surgery. 15 Treatment information described timing and dosing of the concentrate and/or comedication with effect on hemostasis (nonsteroidal antiinflammatory drug, tranexamic acid, or heparin) and achieved FVIII, VWF:Act, VWF:Ag, and VWF:collagen binding levels. Perioperative dosing of the VWF/FVIII concentrate was based on FVIII levels, which were measured by one-stage clotting assays. 13 Dosages and levels obtained after additional desmopressin use were excluded, as FVIII pharmacokinetics after desmopressin were expected to deviate as a result of excessive endogenous FVIII release. 16 The included patients did not receive prophylactic treatment and when occasionally a dose was given before the loading dose of the surgery, this dose was included in the database. A more detailed overview of data characteristics is documented in Table 1 .
| Population PK modeling
The population PK modeling approach analyzes the data from all patients simultaneously instead of modeling individual patients separately. An analysis provides typical (median) values of PK parameters and the corresponding interindividual and intraindividual variability. With this method sparse data with random sampling times, which usually are present during clinical data collection, can be analyzed.
A compartmental population PK model describing the PK of FVIII levels after administration of this specific VWF/FVIII concentrate in the perioperative setting was developed using nonlinear mixed effect modeling, as implemented in software package NONMEM version 7.4.2 (ICON Development Solution). Visualization and evaluation of the data and the developed FVIII PK model were achieved using R v3.4.1 and PsN v4.7.0 in combination with Piraña v2.9.6. [17] [18] [19] [20] Factor VIII levels were log transformed and after analysis the PK parameters, their interindividual variability (IIV), and residual variability between observed and predicted FVIII were derived. In order to determine what number of compartments produced the best fit of the data, single and multiple compartment linear models were used to fit the FVIII versus time data. The PK parameters, volume of distribution (V) and clearance (CL), were estimated. When using, for example, a two-compartment model, estimation of the peripheral volume of distribution and intercompartmental clearance was included.
Baseline FVIII was estimated in the PK analysis and subtracted from the observed FVIII level in the modeling process, though, in 92 of the 180 surgeries, FVIII was measured before administration of the VWF/FVIII concentrate and these values did not always coincide with the measured baseline FVIII: That is, FVIII before administration was often higher than the lowest value ever measured in the patient. This difference is most likely caused by physiological variability in FVIII levels or by preoperative anxiety, increasing age, or presence of comorbidity. [21] [22] [23] For modeling purposes, a correction was introduced by administration of a fixed virtual dose with varying bioavailability to these patients prior to the time of measurement of the predose FVIII level. Application of this technique causes FVIII estimation to return to the lowest value ever measured instead of FVIII level before administration. The rationale of the use of this technique was strengthened by the presence of lower FVIII levels at the end of perioperative treatment than before dose FVIII was measured in 10 occasions. It was possible to estimate the bioavailability (F) and its variability as a correction without influencing estimations of other PK parameters.
Finally, as a wide variatiety of ages and weights was present in the data, the PK parameters were a priori scaled to a body weight of 70 kg using the allometric scaling principle. 24 
| Covariate modeling
In order to test the capability of the factors sex, age, height, blood group, duration and severity of surgical procedure, VWD type, ASA classification, (baseline) VWF:Act, (baseline) VWF:Ag, VWF:CB, use of nonsteroidal anti-inflammatory drugs, tranexamic acid and/or heparin, and altered hepatic function and/or renal function to explain the IIV or interoccasion variability in PK parameter estimates, a covariate analysis using a forward inclusion and backwardselimination method was performed. Using a univariate analysis, potential covariates could be identified and subsequently be included in 
| Model evaluation and validation
The where C pred represents the population predication, C ipred the individual predication, and C obs the observed FVIII for a total number of observations (n). The bias is regarded as non-significant when 0 is included in the confidence interval. Inaccuracy below the arbitrary chosen 25% was accepted.
Subsequently, the FVIII PK model was fully developed after reestimation of all parameter values using all data resulting in the final FVIII PK model. Finally, a bootstrap method was applied, using 1000 data subsets resampled from the complete original data. 
| RE SULTS
| Structural model
A one-compartment linear model best described FVIII PK after administration of the VWF/FVIII concentrate in a perioperative setting. Allometric scaling for body weight was applied to V and CL.
Parameter F successfully corrected for the difference in the baseline FVIII level and the FVIII level observed prior to the surgical procedure without influencing the estimation of the other PK parameters. The IIV was identified in PK parameters V and CL, whereas the interoccasion variability was identified in F. Furthermore, a correlation coefficient was estimated between the variability of V and CL.
Estimated values of this structural FVIII PK model can be found in Table 2 .
| Covariate modeling
During the forward inclusion of the covariate analysis, statistically significant (P < .05) associations were identified between covariates surgery duration, ASA classification and VWF:Act levels over time, and the PK parameter CL. Backward exclusion revealed all associations to be statistically significant (P < .01). When surgery duration increased from 45 to 106 min (interquartile range), CL decreased with 38%. Additionally, when the VWF:Act increased from 0.78 to 2.21 U/mL (interquartile range of all measured VWF:Act levels), CL decreased with 29%, presumably caused by prevention of degradation of FVIII by binding to VWF. The associations between these exponentially modeled covariates and CL are visualized in Figure 1A . In Figure 1C interindividual variability in CL is plotted against VWF activity level and surgery duration.
These plots should show no trend, as this indicates that the covariates explain the variability well. Finally, patients in ASA class III or IV exhibited a 44% decrease of CL in comparison to patients in ASA class II.
(1) 
| Model validation and evaluation
The intermediate PK model based on the index data set was validated with an external data set. The bias and inaccuracy, described by the MPE and MAPE, were found to be −10.2% (95% CI: −14.3 to −6.2) and 13.0% (95% CI: 11.6-14.4). Therefore, the predictive performance of the model in the validation data set showed a small bias and acceptable inaccuracy. The goodness-of-fit plots of the validation (Supplement 1 in Appendix S1) depict the same results and visualize the small bias seen in population prediction versus the observed levels plot and acceptable inaccuracy in the population prediction as well as the individual prediction versus observed levels plot.
Following reestimation of the parameters using all data, goodness-of-fit plots ( Figure 2 ) indicated that the final FVIII population PK model adequately describes FVIII levels of the total study population. In these plots the trend lines are close to the line of identity, indicating that no bias is present and the data are randomly distributed around the line y = x. Figure 2A shows the predicted FVIII levels based on the population PK parameters with covariate adjustment. Since IIV is not taken into account, large deviations from the line y = x are observed. Figure 2B Table 2 .
| D ISCUSS I ON
The aim of this study was to develop a population PK model describing FVIII levels after administration of a specific VWF/FVIII concentrate (Haemate P ® /Humate P ® ) in a perioperative setting.
Additionally, using covariate analysis, any patient, surgical, or treatment factors correlating with the PK parameters of the developed model were identified.
A one-compartment PK model was able to fit the available data describing FVIII levels after administration of the VWF/FVIII is likely superior to the study by Di Paola et al 26 , in which PK-guided dosing of this VWF/FVIII concentrate with a standard two-compartment PK model was evaluated without taking the prior information of the population and influences of covariates into account. 26 A covariate analysis is important as various international guidelines recommend specific FVIII target levels depending on the type and extent of the surgical procedure. 11, 13, 27 Unfortunately, correlation between the presurgical and postsurgical IVR values could not be estimated in this study as presurgical PK profiles were not available.
The effects observed in this study that increasing surgery duration is linked to decreased CL of FVIII, is possibly indicative of an enhanced production or release, or decreased clearance of FVIII (and possibly primarily of VWF) to safeguard hemostasis during longerlasting hemostatic challenges with greater tissue damage. Patients in ASA class III or IV showed a decreased FVIII CL compared to patients in ASA class II. This can possibly be linked to earlier findings that patients with comorbidities exhibit higher VWF and FVIII levels. 23 However, as FVIII baseline levels are included in this population PK model, a decreased FVIII clearance for these patients with more comorbidities would mean that their FVIII levels would rise more during the surgery than those of patients without comorbidities.
This has not yet been observed. In the data used for the covariate analysis no patients were classified in ASA class V (moribund patient not expected to survive 24 hrs with or without an operation) and therefore this class could not be included in the final FVIII population PK model. 28 Observed FVIII:C (IU/mL)
The interaction between VWF and FVIII is complex, considering the variations in the VWF-interactive region located on the light chain of FVIII and possible underlying genetic mutations. 29, 30 Since VWF acts as a chaperone for FVIII, the observed effect of higher VWF:Act levels resulting in decreased FVIII clearances seems logical. 31 Nonetheless, it should be noted that the influence of VWF:Act on FVIII in this PK model is only based on the measured VWF:Act levels, which were assumed to be constant until the next measured level, while in fact VWF:Act levels are expected to change constantly over time after the administration of the VWF/ FVIII concentrate. Furthermore, the high relative standard error (RSE = 51%) of the parameter estimate describing the relationship implies that this observation may be inaccurately estimated. This inaccuracy can be caused by the heterogeneity of VWD types or the absence of sufficient data to describe this association fully.
The effect of VWF:Ag on FVIII PK was also evaluated; however, against expectations this influence was insignificant (Objective Function Value −3.54, P = .05).
Remaining covariates included in the covariate analysis showed no significant associations with PK parameters present in the final FVIII PK model. Minor or major surgery severity was identified as a significant covariate; however, the ASA classification system and surgery duration achieved a higher statistical significance in the multivariate analysis. Von Willebrand disease type was also expected to have a significant influence on the PK parameters.
During univariate analysis, this covariate showed a significant association with CL, as type 2 and type 3, respectively, showed a 54% and 74% higher clearance relative to type 1 patients.
However, this effect was not significant when the other covariates were also included in the model. An earlier study evaluating the PK of the VWF/FVIII concentrate in elective surgery also showed no difference between VWD types and the PK of individual patients. 14 However, we cannot directly compare this study with our current study, as a different PK approach was used and a different loading dose was administrated. One possible explanation could be that VWD type has less effect on the FVIII clearance than ex- 
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